Skip to content

Difelikefalin

Kappa Opioid Receptor Agonist — VARIOUS

Also known as: CR845, difelikefalin acetate, FE202845, kapruvia, korsuva, MR13A9

OnpEMA approvedFDA approvedATC V03AX04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Difelikefalin is an onp drug in the Kappa Opioid Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Opioid kappa Receptor Agonists. DrugCentral lists 2 molecular targets, including Oprk1 and OPRK1. Recorded indications include Pruritus associated with chronic kidney disease (CKD-aP).

  • Approval status: onp (first approved 2021 by the FDA).
  • Drug class: Kappa Opioid Receptor Agonist.
  • Mechanism of action: Opioid kappa Receptor Agonists.
  • Molecular targets: Oprk1 and OPRK1 (2 listed in DrugCentral).
  • Indications: Pruritus associated with chronic kidney disease (CKD-aP).
  • ATC code: V03AX04 (Other therapeutic products).
  • Molecular formula: C36H53N7O6; molecular weight 679.86 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Pruritus associated with chronic kidney disease (CKD-aP)

Mechanism & targets

Mechanism of action (MoA)Opioid kappa Receptor Agonists
Established pharmacologic classKappa Opioid Receptor Agonist

Molecular targets (2)

TargetGeneActionActivity
Kappa-type opioid receptorOprk1agonistEC50 10.32
Kappa-type opioid receptorOPRK1agonistKi 9.49

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2022-04-25EMA—VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
2021-08-23FDA—CARA THERAPEUTICS INC

ATC classification

ATC codeTherapeutic hierarchy
V03AX04VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Other therapeutic products

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Somnolence85.6
Mental status changes75.3
Dizziness58.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Difelikefalin is on its molecule page.

Molecular formulaC36H53N7O6
Molecular weight679.86 g/mol
CAS number1024828-77-0
InChIKeyFWMNVWWHGCHHJJ-SKKKGAJSSA-N
PubChem CID24794466
CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Difelikefalin used for?

DrugCentral lists the following indications for Difelikefalin: Pruritus associated with chronic kidney disease (CKD-aP).

How does Difelikefalin work?

Difelikefalin is classified as Opioid kappa Receptor Agonists; its molecular targets in DrugCentral include Oprk1 (agonist) and OPRK1 (agonist).

When was Difelikefalin first approved?

Difelikefalin was first approved by the FDA in 2021.

What drug class does Difelikefalin belong to?

Difelikefalin is in the Kappa Opioid Receptor Agonist class.

What is the chemical formula of Difelikefalin?

Difelikefalin has the molecular formula C36H53N7O6 and a molecular weight of 679.86 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2021-08-23
AgencyFDA
Targets2
Indications1
FormulaC36H53N7O6
DrugCentral ID5470
Interactive profile